The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Fucoidan is known to have various pharmacological effects, including antitumor activity. Although it has potential as a therapeutic agent for cancer cells, the anti-senescence effects and detailed mechanism of action remain poorly understood in normal hepatic cells. We investigated the anticancer functions of fucoidan using HepG2 cells as well as the mechanisms mediating the anti-senescent actions in Chang liver cells. Fucoidan effectively inhibited HepG2 cell viability and induced apoptosis. Also, fucoidan-induced G₁ phase arrest was caused by the activity of the p16(INK4a)-Rb and p14(Arf)-p53 pathways. Furthermore, upregulation of p16(INK4a) was critical to the antitumor activity of HepG2 cells treated with fucoidan and was correlated with inhibition of Cdk4 and pRb and upregulation of p21 expression. Our results suggest that fucoidan upregulates INK4a locus genes to induce apoptosis through p38 MAPK in HepG2 cells. Moreover, it prevents cellular senescence of Chang-L cells, by decreasing p14(Arf) expression as cells enter quiescence, with the reduction of p16(INK4a). Fucoidan treatment also downregulated the expression of α₂M. In conclusion, fucoidan can be considered a potential therapeutic agent against liver cancer that does not cause senescence in normal hepatic cells. Thus, it may be possible to use fucoidan therapeutically in both tumor suppression and aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 3×
“Senescence is also accompanied by markers associated with replicative exhaustion of normal cells, such as senescence-associated β-galactosidase (SA-β-gal) activity and the induction of p21, p16INK4a and/or p14Arf (16,20).”
BackgroundMethodCellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708 · cited 1×
“The p14Arf-p53 pathway is important as part of the normal life cycle of many cells; it regulates a cell's entrance into senescence (48).”
BackgroundPomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Arf neutralizes the ability of MDM2 to promote p53 degradation, leading to the stabilization and accumulation of p53 (15).”
BackgroundInk4a/Arf expression is a biomarker of aging
Krishnamurthy, J., Torrice, C., Ramsey, M. R., Kovalev, G. I., Al-Regaiey, K., Su, L., & Sharpless, N. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22475 · Cited by 1,486
Fucoidan: Structure and bioactivity
Li, B., Lu, F., Wei, X., & Zhao, R. (2008) · Molecules · doi:10.3390/molecules13081671 · Cited by 1,383
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Stein, G. H., Drullinger, L. F., Soulard, A., & Dulić, V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.2109 · Cited by 868
Cellular senescence and tumor suppressor gene p16
Rayess, H., Wang, M. B., & Srivatsan, E. S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27316 · Cited by 825 · cited 1×
“Thus, cancer cell-specific expression of p16INK4a would be a valuable therapeutic strategy for cancer treatment (9).”
BackgroundINK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442 · cited 1×
“Therefore, the INK4a/Arf locus appears to function as a dualpronged brake to malignant growth, which engages two potent anti-proliferative pathways represented by p16INK4a-pRb and p14Arf-p53 signaling (17).”
BackgroundAccelerated senescence in the kidneys of patients with type 2 diabetic nephropathy
Verzola, D., Gandolfo, M. T., Gaetani, G., Ferraris, A., Mangerini, R., Ferrario, F., Villaggio, B., Gianiorio, F., Tosetti, F., Weiss, U., et al. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90302.2008 · Cited by 302
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Role of p53 in the Regulation of Cellular Senescence
Mijit, M., Caracciolo, V., Melillo, A., Amicarelli, F., & Giordano, A. (2020) · Biomolecules · doi:10.3390/biom10030420 · Cited by 639
“Moreover, p21CIP1 protein levels may lead to the inhibition of Cdk4/6 activity, which contribute to the G1 arrest or senescence [33,34].”
BackgroundTherapies from Fucoidan: An Update
Fitton, J., Stringer, D., & Karpiniec, S. (2015) · Marine Drugs · doi:10.3390/md13095920 · Cited by 418
Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms
Van Weelden, G., Bobiński, M., Okła, K., Van Weelden, W. J., Romano, A., & Pijnenborg, J. M. A. (2019) · Marine Drugs · doi:10.3390/md17010032 · Cited by 330
Immunity, stem cells, and aging
Devaraj, E., Anbalagan, M., Ileng Kumaran, R., & Bhaskaran, N. (2021) · Stem Cells and Aging · doi:10.1016/b978-0-12-820071-1.00006-2 · Cited by 8
Metadata
- Authors
- MIN, E.-Y., KIM, I.-H., LEE, J., KIM, E.-Y., CHOI, Y.-H., & NAM, T.-J.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2014-05-08
- Volume
- 45
- Issue
- 1
- Pages
- 47-56
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2107926413
- Cited by
- 51
- References
- 16
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.